Given the importance of these processes, coupled with the special oncological status of DS individuals — in essence, protection from many types of solid tumors, but increases in the incidence of several hematologic malignancies [52,79,[307], [308], [309], [310]] — the potential oncological implications of inhibiting CBS in DS individuals should also be considered. The gene discussed is CBS; the disease is Dravet syndrome.